GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Institutional Ownership

BeiGene (SHSE:688235) Institutional Ownership : 3.35% (As of Apr. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is BeiGene Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeiGene's institutional ownership is 3.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeiGene's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeiGene's Float Percentage Of Total Shares Outstanding is 0.00%.


BeiGene Institutional Ownership Historical Data

The historical data trend for BeiGene's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Institutional Ownership Chart

BeiGene Historical Data

The historical data trend for BeiGene can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 3.11 3.12 3.14 3.15 3.15 3.15 3.07 3.07 3.05 3.35

BeiGene Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines